UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2020

 

Amgen Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware		001-37702		95-3540776
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

One Amgen Center Drive Thousand Oaks California		91320-1799
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code

(805) 447-1000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value		AMGN		The Nasdaq Global Select Market LLC
1.250% Senior Notes Due 2022		AMGN22		New York Stock Exchange
2.000% Senior Notes Due 2026		AMGN26		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01.

Other Events.

On August 13, 2020, Amgen Inc. (the “Company”) issued a press release announcing the early results of its previously announced private offers to exchange certain outstanding debt securities of the Company for a combination of a cash payment and new debt securities of the Company (the “Exchange Offers”). A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

On August 13, 2020, the Company also issued a press release announcing (i) the pricing terms of the Exchange Offers, (ii) increase of the cap on the aggregate principal amount of new debt securities to be issued in the Exchanges Offers from $800,000,000 to $940,000,000 and (iii) the Company’s acceptance of outstanding debt securities tendered in the Exchange Offers. A copy of the press release is attached as Exhibit 99.2 to this report and is incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

 

Exhibit No.		Document Description
99.1		Press Release dated August 13, 2020.
99.2		Press Release dated August 13, 2020.
104		Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

				AMGEN INC.
Date: August 13, 2020				By:		/s/ Justin G. Claeys
				Name:		Justin G. Claeys
				Title:		Vice President, Finance and Treasurer